Clinical trial
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
Name
RHDIRB2020110301 REC #250
Description
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
Trial arms
Trial start
2024-02-01
Estimated PCD
2025-02-01
Trial end
2025-08-01
Status
Recruiting
Phase
Early phase I
Treatment
N acetyl cysteine
N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
Arms:
treatment group
Size
60
Primary endpoint
The occurrence of cisplatin-induced ototoxicity in the form of hearing loss.
4 cycles of cisplatin (at base line and each cycle range from 21-28 days and or fractionated)
Eligibility criteria
Inclusion Criteria:
* Patients are eligible for inclusion if they meet the following criteria:
* Cancer patients aged \>18 years receiving cisplatin-containing chemotherapy.
* A cisplatin dose starting from 75 mg/m2.
* Various cancer types.
* Both males and females.
* No history of organ transplantation or kidney dialysis.
* Eastern cooperative oncology group performance (ECOG):0-2
Exclusion Criteria:
* Patients with peripheral neuropathy.
* Preexisting unilateral or bilateral moderate to severe sensorineural hearing loss
* Patients with speech discrimination affection or those who are unable to participate in audiologic evaluation
* Co-administration of ifosfamide with cisplatin, because of the known risk of nephrotoxicity.
* Pregnancy or lactation.
* Infection with the human immunodeficiency virus (HIV).
* Prior administration of cisplatin.
* Intraperitoneal chemotherapy.
* Inadequate liver function (bilirubin \> 1.5 times upper normal limit \[ULN\] and alanine transaminase \[ALT\] or aspartate transaminase \[AST\] \> 3 times the upper normal limit \[ULN\] or up to 5.0 upper normal limit \[ULN\] in the presence of hepatic metastases).
* Inadequate renal function (creatinine \> 1.25 times upper normal limit \[ULN\], creatinine clearance \< 50mL/min).
* Serious comorbid systemic disorder incompatible with the study (uncontrolled diabetes mellitus or hypertension, myocardial infarction within the last 6 months).
* Patients diagnosed with kidney cancer.
* Exposure to any nephrotoxic drugs or agents.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2024-03-07
1 organization
1 product
5 indications
Organization
Ain Shams UniversityProduct
N acetyl cysteineIndication
Cisplatin Adverse ReactionIndication
Cisplatin NephrotoxicityIndication
Cisplatin-Induced Peripheral NeuropathyIndication
Cancer PatientsIndication
Cisplatin Ototoxicity